Ovid Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines targeting central nervous system disorders driven by neuronal hyperexcitation, with particular focus on epilepsies, psychoses, and related conditions. The company's pipeline includes OV329, a next-generation inhibitor intended as a successor to vigabatrin for drug-resistant seizures and epileptic encephalopathies, and a portfolio of direct potassium-chloride cotransporter 2 (KCC2) activators—the first of their kind in human studies—being developed for psychosis and mood disorders. Ovid generates revenue through clinical and commercial milestones, strategic partnerships, and licensing agreements; it maintains a lean operational model with manufacturing fully outsourced and commercial capabilities built internally as pipeline assets advance.